An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Researchers used a computer model to predict what happens when people stop taking semaglutide or tirzepatide, two drugs used for weight loss, and the headline conclusion was simple: the model suggests most people would regain much of the weight they lost after stopping the medicines. The report didn’t come from a new clinical trial of real patients coming off treatment; it came from simulations that plug in what we know about the drugs and body weight dynamics to forecast likely outcomes. Semaglutide and tirzepatide are man-made versions of natural signals your body uses to control hunger and blood sugar. Semaglutide mimics a gut hormone that tells your brain you’re full and slows stomach emptying, and tirzepatide acts on two similar hormone systems at once to reduce appetite and improve how the body handles sugar. Both are injected and have been shown in clinical trials to help people lose a significant amount of weight while they take the medications. The new study didn’t enroll patients; it built a mathematical model from existing clinical trial data and biological knowledge to estimate what happens after stopping treatment. The model predicts that, once the drugs are stopped, appetite will gradually return and people will likely regain a large portion of the lost weight over months to years. The exact amount of regain varied across scenarios in the model, but the core finding was consistent: stopping the drugs often leads to substantial weight rebound rather than permanent weight loss. Why this matters is practical. If you’re considering these drugs for weight loss, the model reinforces what some clinicians already suspect: these medicines may need to be continued long-term to keep weight off. That affects decisions about cost, long-term commitment, and expectations. It also matters for doctors and payers when thinking about how to structure treatment plans and support for lifestyle changes alongside medication. There are important caveats. This was a model, not a follow-up of actual people who stopped treatment, so it depends on the assumptions fed into it. Real-world outcomes can differ because of individual habits, lifestyle support, or other medical issues. The drugs have side effects (nausea, stomach upset, rarely more serious problems) and are prescription medications; they aren’t safe or appropriate for everyone. Regulatory approvals and insurance coverage also shape who can access and afford long-term treatment. Bottom line: the best evidence we have so far suggests that weight lost on semaglutide or tirzepatide often comes back if the drugs are stopped, so people and doctors should plan for long-term strategies rather than expecting a one-time cure.
Source: drugtopics.com